Long-Term Mortality and Causes of Death in Isolated GHD, ISS, and SGA Patients Treated with Recombinant Growth Hormone during Childhood in Belgium, The Netherlands, and Sweden: Preliminary Report of 3 Countries Participating in the EU SAGhE Study
Long-Term Mortality and Causes of Death in Isolated GHD, ISS, and SGA Patients Treated with Recombinant Growth Hormone during Childhood in Belgium, The Netherlands, and Sweden: Preliminary Report of 3 Countries Participating in the EU SAGhE Study
复制标题
DOI：
10.1210/jc.2011-2882
复制
发表时间：
2012-02-01
影响因子：
5.8
通讯作者：
Hokken-Koelega, Anita
中科院分区：
文献类型：
--
作者：
Savendahl, Lars;Maes, Marc;Hokken-Koelega, Anita
背景：儿童时期接受重组生长激素治疗的成人的长期死亡率研究不足。最近发布的数据来自欧盟法国部分的GH治疗在欧洲的安全性和适当性（EU SAGhE）研究引起了对GH治疗长期安全性的关注。目的：报告在比利时、荷兰，儿童期接受GH治疗的孤立性GH缺乏症或特发性身材矮小或出生时小于胎龄儿患者的长期生命状态和死亡原因的初步数据，设计：从GH治疗患者的国家登记处和国家人口登记处的生命状态中检索数据。从国家死因登记处（瑞典）、联邦和地区死亡登记处（比利时）或个体患者记录中检索死亡原因（荷兰）。所有诊断为单纯性GH缺乏症或特发性身材矮小或出生时小于胎龄的患者在儿童期从1985年开始接受重组GH治疗，1997年和2010年底年满18岁的人被纳入。这2,543例患者中约98%的患者可获得生命状态，相当于46,556人-年的观察。主要结果测量：评估生命状态、死亡原因、死亡年龄、死亡年份、GH治疗持续时间和治疗期间的平均GH剂量。在21例死亡病例中，12例死于意外，4例自杀，1例死于肺炎、内分泌功能障碍、原发性心肌病、体液免疫缺陷和凝血功能缺陷。在这些队列中，大多数死亡（76%）是由事故或自杀造成的。重要的是，没有患者死于癌症或心血管疾病。（临床内分泌代谢杂志97：E213-E217，2012）
Context: The long-term mortality in adults treated with recombinant GH during childhood has been poorly investigated. Recently released data from the French part of the European Union Safety and Appropriateness of GH treatments in Europe (EU SAGhE) study have raised concerns on the long-term safety of GH treatment.Objective: To report preliminary data on long-term vital status and causes of death in patients with isolated GH deficiency or idiopathic short stature or born small for gestational age treated with GH during childhood, in Belgium, The Netherlands, and Sweden.Design: Data were retrieved from national registries of GH-treated patients and vital status from National Population Registries. Causes of death were retrieved from a National Cause of Death Register (Sweden), Federal and Regional Death Registries (Belgium), or individual patient records (The Netherlands).Patients: All patients diagnosed with isolated GH deficiency or idiopathic short stature or born small for gestational age started on recombinant GH during childhood from 1985-1997 and who had attained 18 yr of age by the end of 2010 were included. Vital status was available for approximately 98% of these 2,543 patients, corresponding to 46,556 person-years of observation.Main Outcome Measure: Vital status, causes of death, age at death, year of death, duration of GH treatment, and mean GH dose during treatment were assessed.Results: Among 21 deaths identified, 12 were due to accidents, four were suicides, and one patient each died from pneumonia, endocrine dysfunction, primary cardiomyopathy, deficiency of humoral immunity, and coagulation defect.Conclusions: In these cohorts, the majority of deaths (76%) were caused by accidents or suicides. Importantly, none of the patients died from cancer or from a cardiovascular disease. (J Clin Endocrinol Metab 97: E213-E217, 2012)